Phase 2 trial of S-adenosyl methionine vs placebo for 180 days in 63 people with MCI or dementia due to Alzheimer's disease: no significant difference in change in plasma p-tau217 (p=0.288), safety or secondary cognitive outcomes; it was well tolerated.
RCTn = 63
Holper et al. A phase 2, randomized, multicenter, double-blind, placebo-controlled trial of S-adenosyl methionine in participants with mild cognitive impairment or dementia due to Alzheimer's disease